TOKYO, Mar 25, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of early Alzheimer’s disease (early AD *) has received the Prime Minister’s Awar […]